Authors have pulled a paper on an antifungal drug that is potentially toxic because it lacked final approval from their institution.
The study describes a patient who had experienced liver toxicity after taking voriconazole. During the study, the authors re-administered the drug to the patient using “a slow dose titration.” But their institution didn’t approve the study before it was published online.
Here’s the retraction note for “Successful Rechallenge with Voriconazole following Medication-Induced Hepatotoxicity,” published in Antimicrobial Agents and Chemotherapy. Continue reading Antifungal drug paper didn’t have institution’s approval
We can’t resist flagging some misleading language in a retraction note for a 2015 paper on the inner workings of an amoeba pathogen.
The note for “The Charms of the CHRM Receptors: Apoptotic and Amoebicidal effects of Dicyclomine on Acanthamoeba castellanii” is short, so we’re going to give it to you up front:
This accepted manuscript has been retracted because the journal is unable to verify reviewer identities.
Sounds like another case of faked emails to generate fake peer reviews, right? But that’s not what happened to this paper, according to the editor in chief of Antimicrobial Agents and Chemotherapy, Louis B. Rice, a professor at Brown University:
Continue reading Editors weren’t “unable to verify reviewer identities” — reviewers just weren’t qualified